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Abstract: Clostridium perfringens causes one of the most common foodborne illnesses, 
which is largely mediated by the Clostridium perfringens enterotoxin (CPE). The toxin 
consists of two functional domains. The N-terminal region mediates the cytotoxic effect 
through pore formation in the plasma membrane of the mammalian host cell. The   
C-terminal region (cCPE) binds to the second extracellular loop of a subset of claudins. 
Claudin-3 and claudin-4 have been shown to be receptors for CPE with very high affinity. 
The toxin binds with weak affinity to claudin-1 and -2 but contribution of these weak 
binding claudins to CPE-mediated disease is questionable. cCPE is not cytotoxic, however, 
it is a potent modulator of tight junctions. This review describes recent progress in the 
molecular characterization of the cCPE-claudin interaction using mutagenesis, in vitro 
binding assays and permeation studies. The results promote the development of 
recombinant cCPE-proteins and CPE-based peptidomimetics to modulate tight junctions 
for improved drug delivery or to treat tumors overexpressing claudins. 
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1. Introduction 
Clostridium perfringens enterotoxin (CPE) causes the gastrointestinal symptoms of C. perfringens 
type A food poisoning, which is one of the most common foodborne illnesses in the USA and Europe. 
OPEN ACCESS Toxins 2010, 2                               
 
 
1337 
In addition, CPE is thought to contribute to diarrhea that is associated with antibiotic treatment, and to 
cause gastrointestinal illness frequently in domestic animals [1,2]. CPE binds to transmembrane 
proteins on human ileal epithelium [3]. These CPE-receptors are claudin-3, -4 (Cld3, -4) and some 
other members of the claudin family, which are tight junction (TJ) proteins. After binding,  pore 
formation in the plasma membrane of the host mucosa cell leads to fluid and electrolyte loss along 
with epithelial cell death and the known clinical symptoms of CPE-intoxication [3]. 
A C-terminal fragment of CPE (cCPE) is not cytotoxic but still binds to certain claudins and 
modulates the function of TJ formed by claudins mainly. Treatment of epithelial monolayers with  
non-cytotoxic cCPE increases paracellular permeability [4]  and enhances drug absorption in rat 
jejunum 400-fold relative to sodium caprate, which is in clinical use [5]. cCPE removes its receptor—
Cld4—specifically from tight junctions while distribution of those claudins that do not bind cCPE are 
unaffected [4]. The cCPE-induced subtype-specific removal of claudins, and therefore the opening of 
TJ, is mediated by a different mechanism than cytotoxicity of full length CPE. This is concluded 
because the opening is slow, reversible and does not affect integrity of the plasma membrane, while 
the toxicity is caused by fast and irreversible increase in membrane permeability. These findings have 
implicated cCPE as a pharmacological tool (i) to modulate tight junctions to improve drug delivery 
across tissue barriers and (ii) for treatment of tumors overexpressing claudins. In this review, the 
Clostridium perfringens enterotoxin and its cellular receptors (defined claudin subtypes) are described. 
Here, the focus is a summary of recent progress in molecular characterization of the cCPE-claudin 
interaction that can be used for an improved design of CPE-based modulators of claudins. 
2. Clostridium perfringens and Its Toxins 
The gram-positive bacterium Clostridium perfringens  is a human and veterinary pathogen [6].  
C. perfringens  produces at least  14 different protein toxins [6]. Alpha toxin, produced by all 
toxinotypes of C. perfringens, has hemolytic and lethal activities [7]. It is the primary mediator of gas 
gangrene caused by C. perfringens [8]. Toxinotypes B and C produce pore-forming beta toxin [9], 
shown to be lethal in a mouse model [10]. Types B and D express epsilon toxin, which is also a pore 
forming toxin [11–13]. Type E of C. perfringens produces iota toxin with ADP-ribosyltransferase 
activity. 
Additionally, CPE is deemed to be the C. perfringens toxin that is most relevant for pathologic 
effects in human intestines. Unlike the other toxins, CPE is produced only by sporulating cells and 
accumulates in a large inclusion body inside the mother cell, from which it is released after lysis at the 
end of sporulation [14,15]. It causes the symptoms of C. perfringens type A food poisoning and those 
of non-foodborne gastrointestinal illnesses. A correlation between food poisoning and C. perfringens 
was first established in the 40s and 50s of the 20th century. The poisoning effect was demonstrated 
after development of the rabbit ileal loop model in 1968 [16] and the ability to cause diarrhea in 
humans was shown in 1971 [17]. Later on, purified CPE was confirmed to be responsible for diarrhea 
in animal models [18] and humans [19]. In addition, knock-out mutants confirmed CPE to be the toxin 
responsible for disease caused by CPE-positive strains [20].  Toxins 2010, 2                               
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3. Clostridium perfringens Enterotoxin (CPE) 
CPE is a single polypeptide with 319 amino acids and a molecular mass of 35 kDa [21]. Significant 
homology to any other bacterial toxins is neither recognized on the DNA nor on the protein level. 
However, on the amino acid level, it has 27% identity and 46% similarity to the non-toxic 
hemagglutinin components of the type C. botulinum toxin [22]. 
Intoxication by CPE causes, firstly, inhibition of absorption of ions and fluid by intestinal epithelial 
cells and, secondly, death of these cells leading to secretion of fluid into the intestinal lumen [23]. The 
pathophysiological and cellular effects of CPE were studied in animal models, such as rat and rabbit 
ileum [24], and sections of human intestine were examined ex vivo [3] and in vitro with cell lines, e.g., 
Vero cells and human colon carcinoma cells Caco-2 cells [25]. The Caco-2 cells have the advantage 
that they show characteristics of enterocytes since they form complete TJ and microvilli brush borders 
like native intestinal epithelial cells. Using Caco-2 cells grown on Transwell® permeable supports, it 
could be shown that CPE-incubation is 2–3 times more effective  after basolateral application in 
comparison to the apical application [25]. CPE-incubation leads to the lysis of cultured epithelial cells 
from intestine, liver and kidney [26,27]. 
The first step of CPE-induced toxicity is the binding of CPE to its receptors on the surface of  
CPE-sensitive cells. The TJ proteins Cld3 and Cld4 have been identified to be cellular receptors for CPE 
[28]. After association of CPE with its receptors, a 90 kDa SDS(sodium dodecylsulfate)-sensitive 
“small complex”, containing CPE  and claudins is formed [29,30].  Oligomerization  of the “small 
complex” is proposed to result in formation of a 155 kDa SDS-resistant “large complex” [28–30]. This 
leads to a massive increase in membrane permeability for molecules <200 Da. It was suggested that 
CPE - as part of the 155 kDa complex - partially integrates in the plasma membrane, thereby leading to 
formation of a transmembrane pore [31,32]. The Ca
2+ influx through this CPE-pore results in cell 
damage. It was proposed that this damage provides CPE access to TJ and leads to formation of a  
200 kDa complex containing occludin and to internalization of TJ proteins. TJ damage and cell death 
by apoptotic and oncotic processes increase paracellular permeability and thereby contribute to the 
diarrhea of CPE-induced gastrointestinal disease [25,33]. Using gel shift assays and size exclusion 
chromatography, the 155 kDa complex was resized as ~425–500 kDa and suggested to consist of 12 
claudin and six CPE molecules. The 200 kDa complex was resized as a ~550–660 kDa complex [29].  
3.1. Functional domains of CPE 
Two major domains have been functionally distinguished in CPE: the N-terminal half shares several 
structural similarities with ß-poreforming toxins [32]  and mediates the cytotoxicity,  whereas the   
C-terminal half contains the claudin-binding domain [34]. Analysis with recombinant deletion mutants 
of CPE revealed the region meditating the different activities of CPE in more detail. The 44 N-terminal 
amino acids have an inhibitory effect on the cytotoxicity [34]. The region 45–167 is involved in 
membrane insertion as well as “large complex”- and pore-formation. More precisely, a specific region 
between D45 and S59 is required for the formation of the “large complex” [2,34,35]. The region 81 to 
106 is essential for pore formation [32]. Toxins 2010, 2                               
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3.2. C-terminal claudin-binding domain of CPE  
The C-terminal region 290–319 is sufficient for binding to claudins,  as  was  shown with 
corresponding recombinant C-terminal CPE-fragments and respective synthetic peptides [36]. 
Removal of these 30 C-terminal amino acids inhibited binding to claudins completely [34]. However, 
longer CPE-fragments interact much stronger with claudins than cCPE290–319 [37].  Van Itallie and 
colleagues solved the crystal structure of cCPE194–319, which most likely contains the complete claudin-
binding domain [38]. This domain comprises the residues A205–F319  and  forms a nine-strand  
β-sandwich. The core claudin-binding region—S290–F319—is formed by strands β8 and β9, which 
are located in the center of the opposing beta sheets, and the surface loop between these strands. 
Consequently, peptides restricted to the amino acids 290–319 are not expected to have the same 
conformation as the corresponding region in the full beta sandwich. This explains, at least partly, why 
cCPE290–319 binds more weakly to claudins than longer cCPE-fragments [37].  
The structure of cCPE194–319 shows similarities to the receptor-binding domains of other bacterial 
toxins [38]. This was unexpected, since no strong homology to these proteins is given at the amino 
acid sequence level. However, similarities in the 3D structure, e.g., to those domains within the ColG 
collagenase of Clostridium histolyticum [39] and the Cry4Ba toxin of Bacillus thuringiensis [40], 
suggest a common evolutionary origin. 
4. The CPE-Receptors: Claudins 
The cellular receptors for CPE were discovered by the pioneering work of Katahira et al. [41]. In 
their expression cloning approach, a cDNA library from CPE-sensitive Vero cells was introduced in 
CPE-insensitive fibroblasts. The transfectants were incubated with recombinant cCPE  and those 
expressing a CPE-receptor sorted by  fluorescence activated cell sorting (FACS). The transfected 
plasmids were recovered, sequenced and the ability of the encoded protein to bind CPE was verified. 
This resulted in identification of the CPE-receptor, CPE-R  [41].  Further sequence analysis and 
screening revealed that the androgen withdrawal apoptosis protein (RVP1) is structurally related to 
CPE-R and an additional receptor for CPE, CPE-R2 [28]. Later, both were characterized as members 
of the claudin (Cld) protein family, namely Cld4 and Cld3 [42]. Other family members, e.g., Cld1 or -2 
were originally described not to bind to CPE: fibroblasts transfected with Cld1 or -2 did not show clear 
CPE-binding nor CPE-induced cell death [4,43]. However, recently, both have been demonstrated to 
bind with weak affinity to CPE (see below and [44]). To date, 24 subtypes of claudin were identified in 
mammalian cells. They are known as tetraspan membrane proteins with two extracellular   
loops (ECLs). 
Claudins form the backbone [45] of TJ, cell-cell junctions in the apical part of the lateral plasma 
membrane in epi- and endothelia. TJ form a belt-like seal around each cell that limits and regulates 
paracellular permeability and that is essential for tissue barriers. TJ appear as fusions of the 
membranes of two neighboring cells (transmission electron microscopy) and as a continuous network 
of strands of transmembrane proteins [46]. Occludin [47], tricellulin [48] and marvelD3 [49] are other 
tetraspan transmembrane TJ proteins. Scaffolding proteins like zonula occludens proteins (ZO1–3) and 
signaling proteins are associated with TJ as, for instance, by binding of their PDZ-domains to Toxins 2010, 2                               
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respective binding motifs at the C-terminus of claudins [45]. These membrane associated proteins 
regulate assembly and disassembly of TJ [50,51]. Claudins are known to tighten the paracellular cleft 
size- and charge-selectively and can be functionally divided in barrier-forming, e.g., Cld1, -3, -4, -5, 
and pore-forming claudins, e.g., Cld2, -7,  -10,  -16  [45]. Expression of barrier-forming claudins 
decreases paracellular permeability of ions, solutes and proteins in a subtype-specific manner. In 
contrast, pore-forming claudins increase paracellular permeability for ions, e.g., Cld2 for monovalent 
cations. The tissue-specific combination of claudin subtypes expressed in a given tissue is assumed to 
determine the permeability properties of the TJ [45]. Residues in the first extracellular loop (ECL1) of 
claudins determine the ability to form paracellular ion pores as well as their charge selectivity [52]. 
Claudins copolymerize in heteropolymers by homo-  and heterophilic interactions between the 
subtypes by different modes of action. cis-interaction (between molecules along one membrane) and 
trans-interaction (between molecules of two opposing cell membranes) contribute to the formation of 
polymeric intramembranous TJ strands [45,53]. The pattern of heterophilic compatibility of different 
claudin-subtypes is just partly known. However, assays applying cellular reconstitution of TJ-strands, 
confocal analysis of subcellular distribution and FRET (fluorescence resonance erergy transfer) of 
claudins as well as electron microscopy are used to investigate pattern and mechanism of claudin 
polymerization in more detail [53,54].  
On the amino acid sequence level, two subgroups of claudins can be distinguished. Classic claudins 
(Cld1 up to -10, -14, -15, -17, -19) share higher homology among each other than non-classic claudins 
(Cld11,  -12,  -13,  -16,  -18,  -20 up to -24)  [45]. Classic claudins are likely to share a common   
helix-turn-helix structure of the ECL2 that is involved in paracellular tightening [54–56]. Since the 
structure of claudins is unknown, a molecular model of the ECL2 was generated by combination of 
cell biological analysis of claudin mutants and bioinformatics homology modeling [45,54,57]. As an 
example,  for classic claudins, a model of Cld5 based on high sequence homology to the  protein 
BB2244 from Bordetella bronchiseptica  and the corresponding crystal Structure (2BDV) was 
developed. This model was also consistent with experimental data, since it could explain folding 
defects of the Cld-5-ECL2 mutants analyzed. This model predicted a helix-turn-helix structure. 
Furthermore, a model of an ECL2-trans-dimer of Cld5 was derived from experimental data 
demonstrating that defined residues in the ECL2 are essential for trans-interaction of the protein [54]. 
In particular, aromatic residues of two opposing ECL2 form an aromatic core which is necessary for 
trans-interaction. Strikingly, the residues suggested to be involved in folding and in trans-interaction, 
are highly conserved among classic claudins [45]. This supports the assumption that the structure of 
the ECL2 and the mechanism of trans-interaction is, at least, partly similar for all classic claudins.  
In particular, experimental data and modeling suggested a helix-turn-helix structure for the ECL2 of 
the CPE-binding Cld3 (Figure 1 and [37]), similar to the one of Cld5 [54]. Since CPE binds to the 
ECL2 of Cld3 [43], the molecular model of the Cld3-ECL2 can be used to analyze the CPE-claudin 
interaction in more detail [37].  Toxins 2010, 2                               
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5. The Interaction between Clostridium perfringens Enterotoxin and Claudins  
5.1. Methods used to investigate interaction between CPE and claudins 
To investigate the interaction between CPE and claudins different methods have been  applied. 
These are described and compared in the following sections. 
5.1.1. Use of peptides in arrays and surface plasmon resonance spectroscopy 
Synthetic peptides have been used to investigate CPE-claudin interactions. This is a useful strategy 
since the minimal claudin binding region of CPE as well as the CPE-binding ECL2 of claudins are 
relatively short, 30 and 15–25 amino acids, respectively (for details see Chapters 5.2 and 5.3). Arrays 
of immobilized 15–20  mer ECL2 peptides where incubated with recombinant GST-CPE fusion 
proteins to identify residues in the ECL2 responsible for CPE-binding [37]. For quantitative analysis of 
binding surface plasmon resonance spectroscopy (SPR) ECL2 peptides were immobilized on biacore 
sensor chips and superfused with recombinant GST-CPE fusion proteins. Similarly, CPE290–319 
peptides were immobilized and superfused with recombinant Cld4 proteins to define structural 
constraints in Cld4 for CPE-binding [58].  
However, peptides often do not have the native conformation as it occurs in the full length protein. 
This is of particular importance for claudins, since the short ECL2 is forced to form a loop structure by 
the adjacent transmembrane domains. Similarly, CPE290–319 peptides cannot form the native binding 
domain, due to missing essential β-strands [37,38]. Hence, results obtained with peptides have to be 
verified by assays using full length proteins or constructs shown to form the relevant domains.  
5.1.2. Pull-down assays 
Pull-down assays are widely used for analysis of interaction between cCPE and full length claudins. 
These assays can be performed in  different ways. (i) In some studies,  lysates of cells expressing   
full-length Cld4 were incubated either with His-tagged cCPE-wt or cCPE-mutant, and then mixed with 
Ni-resin beads. Bound proteins were analyzed by SDS-PAGE (polyacrylamide gel electrophoresis) 
followed by Western blot [59,60]. (ii) Other authors use tagged claudins—Van Itallie et al. reported 
using His-tagged Cld4—to immobilize protein molecules on beads and afterwards to incubate the 
beads with purified cCPE. Eluted Cld4–cCPE complexes were further resolved by SDS-PAGE and 
detected by Coomassie Brilliant blue staining [38]. (iii) GST-tagged cCPE bound to gluthatione-
sepharose beads was incubated with human embryonic kidney (HEK)-293 cells, transiently transfected 
with Cld3. Eluted cCPE–Cld3  complexes and unbound fractions were analyzed by means of   
SDS-PAGE and Western-blot [37]. In addition, pull-down assays were performed with lysates of cells 
expressing endogenous claudins [60,61].  
Pull-down assays have the disadvantage to depend on detergent solubilization of the transmembrane 
claudin proteins. It has to be considered that detergents can strongly alter the conformation of 
transmembrane proteins and, thereby, change the interaction properties of proteins. Moreover, 
compared to binding assays with purified recombinant proteins or peptides (see Chapter 5.1.1), one 
cannot exclude interference by other proteins. Toxins 2010, 2                               
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5.1.3. Cellular binding assays 
Cellular binding assays, in comparison to pull-down assay, allow investigation interaction of cCPE 
with full length claudins in their native membrane environment. Either cells expressing endogenous 
claudins, like Caco2 cells, or claudin-transfected cells can be used. Cells with endogenous claudins and 
functional tight junctions have the advantage that they form a physiologically relevant cellular barrier. 
However, claudin-transfection of cells without endogenous tight junction proteins enables the analysis 
of individual claudins without interference of other tight junction proteins. 
Claudin-expressing  cells  are incubated with CPE-constructs, washed, lysed and the lysates are 
resolved by SDS-PAGE and analyzed by Western blot for the amount of bound CPE and expressed 
claudins [37] Alternatively, CPE-binding can be detected by measuring the radioactivity of I
125-labeled 
CPE [41].  
The following assays are also based on the CPE-binding to cellular claudins: 
5.1.3.1. Assay of CPE cytotoxicity 
The cytotoxic effect of CPE-constructs is used to measure their activity [62]. Either full-length CPE 
or cCPE fused to a toxic effector domain of another protein, e.g., synthesis inhibitory factor (PSIF), is 
incubated with cells expressing claudins of interest. These are either cells expressing endogenous 
claudins such as Caco-2 and Marbin Darby canine kidney (MDCK) cells, or claudin-transfected 
HEK293 and L-cells, both without endogenous claudins. The cell death as a measure for CPE-binding 
is determined by assessing cell membrane integrity. One common way is to evaluate the release of 
lactate dehydrogenase (LDH) from dead cells to the culture medium [59,60,63]. 
5.1.3.2. Competition binding assay 
A modification of the method mentioned above uses competition of binding partners. For instance, 
the cytotoxic cCPEwt-PSIF competes with non-toxic cCPE-constructs for binding to claudin-expressing 
cells  [59,60]:  the  better the non-toxic cCPE-construct interacts with its receptor,  the stronger the 
inhibition of cCPEwt-PSIF binding and the lower the cytotoxic readout. In this assay,  cells are 
pretreated with the cCPE-construct of interest then incubated with cCPEwt-PSIF, and afterwards, cell 
death is measured by LDH release. 
In another approach, different claudin-constructs compete for binding to cCPE [62]. In this assay, 
cCPE is pretreated with solubilized recombinant claudin proteins before it is applied to cells 
expressing native claudins.  
5.1.4. Methods for investigation of cCPE effects on paracellular permeability 
Since it is well known  that the CPE-receptors (claudins) constitute the backbones of TJ in 
membranes of epithelial and endothelial cells, it is possible to detect the effect of cCPE on living cells 
via measuring the TJ integrity. Disruption of TJ integrity due to formation of cCPE–claudin complexes 
can be registered via measuring the transepithelial electrical resistance (TEER) of a monolayer of 
claudin-expressing cells. Additionally, detection of permeation of labeled molecules, e.g., fluorescein, 
through the monolayer, is used [37,60,64,65]. This method was, for instance, used to show that   Toxins 2010, 2                               
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GST-tagged cCPE increases the paracellular permeability of fluorescein through the monolayer of 
Caco-2 cells compared with GST itself [37].  
Permeation of labeled molecules, e.g.,  fluorescein or fluorescein-isothiocyanate-dextran (FD), 
across cellular sheets after application of cCPE-constructs can be detected also in vivo. For such 
assays, the jejunal loop of rats is used most commonly. During the experiment, the lumen of the 
jejunum is washed with saline and the jejunal loop is prepared by closing both ends with sutures, then 
a mixture of FD and cCPE is administered into the jejunal loop. cCPE alters the integrity of TJ in 
epithelial cells and, thereby, molecules of FD can reach the blood by crossing the epithelium 
paracellularly. At several time points thereafter, blood is collected from the jugular vein and plasma 
concentration of FD is determined with fluorescence spectrophotometer [59,60,65].  
5.2. Residues in CPE involved in binding to claudins  
All methods listed in Chapter 5.1 are used to investigate CPE-claudin interaction. As mentioned in 
Chapter 3.2, it was shown that the 30 C-terminal amino acids of CPE (β8-loop-β9-region) are essential 
for binding to claudins. Involvement of residues within this region in binding to claudins has been 
demonstrated in several studies [35,59,60,63,66]. For instance, it was found that upon deletion of 16  
C-terminal amino acids, cCPE loses its ability to interact with Cld4 [67]. The substitution Y310C 
reduced binding of CPE to brush border membrane in rabbit intestine [35]. Harada et al. revealed 
inhibition of binding and toxicity of cCPE-PSIF [63] in competition assays by substitutions Y306A, 
Y310A or Y312A [59]. Additionally, this study applied a  pull-down assay to show that single 
mutations Y306A, Y310A or Y312A and double mutation Y310A/Y312A resulted in partial reduction 
of Cld4 binding. Furthermore, double mutants Y306A/Y310A and Y306A/Y312A, as well as triple 
mutant Y306A/Y310A/Y312A,  lost the ability to bind to Cld4. Measurements of transepithelial 
resistance of cultured cells and in situ loop assays showed inhibition of TJ-opening by the multiple 
tyrosine mutations [59]. Y306K, but not Y306F substitution interfered with claudin binding [66]. 
Taken together, these results showed that Y306 is the pivotal residue for binding to claudins, where the 
aromatic ring and not the functional hydroxyl group is essential. However, all three tyrosine residues 
(Y306, Y310 and Y312) contribute to the interaction of cCPE with Cld4 and to the modulation of TJ 
barriers [59].  
Systematic analysis of each of the last 16 C-terminal amino acids was performed to reveal other 
residues possibly involved in binding to claudins [60]. By replacing individual amino acids with 
alanine it was found that L315, in addition to the previously reported tyrosines, is critical for binding to 
Cld4, modulating TJ-barrier function and enhancing jejunal absorption.  The crystal structure of 
CPE194–319 revealed that Y306, Y310, Y312 and L315 form a hydrophobic pit on the surface of CPE, 
which is obviously involved in claudin binding [37,38].  
5.3. Residues in claudins involved in interaction with CPE  
Soon after the identification of Cld3 and Cld4 as CPE-receptors it was demonstrated that CPE does 
not bind to all claudin subtypes. In particular, binding to Cld3 and Cld4 but not to Cld1 and Cld2 was 
reported [4]. The association constants for the binding of CPE to Cld3, -4, -6, -7, -8 and -14 were 
determined to be 8.4  ×  10
7  M
-1, 1.1  ×  10
8  M
-1, 9.7 × 10
7  M
-1, 8.8 × 10
7  M
-1, 1 × 10
6  M
-1  and  Toxins 2010, 2                               
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1 × 10
6 M
-1, respectively [4,43]. Recently, detectable binding to Cld1, Cld2 [44] and Cld9 [37] has 
been demonstrated also. However, CPE-binding to Cld1 and -2 is much weaker than that to Cld3 and  
-4. For Cld5 no interaction with either full length CPE or CPE194–319 was obtained [37]. However, 
binding of CPE to Cld5 was detected with GST-CPE116–319 [37] containing more amino acids than the 
well described claudin-binding domain (194–319). It was suggested that the very weak  affinity 
between cCPE and Cld5 is presumably enhanced by multivalent binding of GST-CPE116–319-oligomers 
[37]. Different results concerning CPE-binding of the diverse claudin subtypes could be obtained due 
to differences in the CPE-constructs and the sensitivity of the assay used. However, Cld3, -4, -6, -7, -8 
and -9 (controversial for Cld8) can be considered to be high affinity CPE-receptors; Cld1, -2, -5, -8 
and -14 (controversial for Cld5 and Cld8) to be low affinity CPE-receptors and Cld10–13 as well as 
Cld15–24 apparently do not interact with CPE.  
To date, it is well known that the ECL2 of CPE-sensitive claudins is involved in binding with 
enterotoxin. In different independent studies it was confirmed that CPE interacts with the ECL2 of 
Cld3 and -4, but not (strongly) with those of Cld1 and -2 [43,62]. In addition, CPE does not recognize 
ECL1 of Cld3 and -4 [43,44]. Recently, residues in the ECL2 of CPE-binding claudins, involved in the 
interaction with CPE, were identified by amino acid substitutions in ECL2 of claudins [37]. Arrays 
with immobilized Cld3-ECL2 peptides were incubated with GST-cCPE. Substitution of D149 and 
T151 in murine Cld5 by the corresponding residue of Cld3 (N148, L150) enabled the binding of cCPE 
to Cld5. Similarly, substitution S149N in murine Cld2 led to binding of GST-cCPE.  
Furthermore, substitution mapping was performed to reveal the role of residues in Cld3-ECL2 in 
interaction with cCPE. Each position of Cld3-ECL2 peptide was substituted with every other amino 
acid except cysteine. This mapping identified the motif 148NPLVP152 as essential for binding of 
cCPE to Cld3-ECL2 peptides. Moreover, pull-down and cellular binding assays verified strong 
involvement of N148 and L150 in interaction between CPE and native Cld3 [37]. Sequence 
comparison  revealed that all cCPE-binding  subtypes of claudin contain the consensus sequence 
NP(L/M)(V/L/T)(P/A) in the turn region of the predicted helix-turn-helix structure of the ECL2 
(Chapter 4 and [54]). Strikingly, all claudins, which are able to interact with cCPE, belong to the group 
of classic claudins [45]. As mentioned above (Chapter  4),  the classic claudins probably share a 
common helix-turn-helix structure. This appears to be a precondition for CPE-binding, since non-
classic claudins, which have most likely a different fold, do not bind [37]. However, differences within 
this helix-turn-helix structure have to determine the ability to interact with cCPE. The positions 2, 4 
and 5 in the identified consensus sequence (P, V/L/T and P/A) are highly conserved among classic 
claudins and, according to the model, are involved in stabilization of the turn region of the loop 
structure. In contrast, the NH2-group of arparagine at position 1 and side chain of leucine/methionine 
at position 3 point away from the loop. In all CPE-sensitive claudins,  but in nearly none of the   
CPE-insensitive claudins, asparagine is present at position 1 and leucine or methionine at position 3 of 
the consensus sequence. Taken together, the discussed data demonstrate that the residues 
corresponding to N148 and L150 in murine Cld3 are strongly involved in the CPE-claudin interaction. 
Subsequently, other studies verified the importance of the asparagine in the proposed consensus 
sequence. The substitution N149D in full length human Cld4 abrogated the binding of CPE [62]. 
Conversely, the corresponding D150N substitution in human Cld1 as well as S149N in human Cld2 
strongly increased binding of CPE [62]. Kimura et al. analyzed several claudin chimera of Cld5 and Toxins 2010, 2                               
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Cld4 including D149N substitution in human Cld5 [44].  These data are also  consistent with 
conclusions mentioned above. 
Table 1.  Capacity of claudin subtypes and mutants thereof to  interact with   
CPE-constructs. For the claudin constructs the nomenclature of the respective source is 
given. The respective sequence is given in the left column. It corresponds to W139-W169 
of human Cld1 and contains the predicted ECL2, W139-Q163 [45]. Amino acids which 
differ from the corresponding amino acids in Cld3 and Cld4 (high affine receptors) are 
highlighted in red. Color code for binding capacity: blue: Assays based on peptides of 
claudins or CPE;  yellow/orange:  assays based on detergent-solubilized claudins; 
green: cellular-binding assays. The color shade corresponds to the following categories 
of binding capacity: 0–10% (-), 10–25% (low), 25–85% (medium) and >85% (high) of 
bound CPE relative to Cld3wt or Cld4wt. Entries marked with an asterisk were derived by 
cytotoxicity assays and the categories are defined as: highly sensitive (high),   
EC50 < 1 µg/mL; slightly sensitive (low), 1 µg/mL < EC50 < 30 µg/mL; and insensitive, 
30 µg/mL < EC50 [43]. In some cases, no further quantification of the amount of bound 
CPE was available (+). All constructs without prefixes are derived from mouse sequences, 
the other constructs are derived from human (hu-); monkey (mk-); mouse/human chimaeras 
(muh-). monkey/human chimeras (mkh-). (p) indicates data obtained with CPE290–319, (L) 
data obtained with CPE116–319; all other data were obtained with full length CPE or 
constructs similar to CPE194–319.  
ECL2-sequence  Claudin  construct  Binding capacity  Source 
WYGNRIVQEFYDPLTPINARYEFGQALFTGW  1  wt  - (L)  Winkler et al., 2009 [37] 
WYGNGIVQEFYDPLTPINARYEFGQALFTGW    Cldn1  low *  Kimura et al., 2009 [44] 
WYGNRIVQEFYDPMTPVNARYEFGQALFTGW    hu-Cldn1  low *  Kimura et al., 2009 [44] 
WYGNRIVQEFYNPLVASGQKREMGASLYVGW    mkh-Cldn1-4-1(A)  high *  Kimura et al., 2009 [44] 
WYGNRIVQEFYNPLVASGQKREMGAALFTGW    mkh-Cldn1-4-1(B)  high *  Kimura et al., 2009 [44] 
WYGNRIVQEFYDPLVASGQKREMGAALFTGW    mkh-Cldn1-4-1( C)  low *  Kimura et al., 2009 [44] 
WYGNRIVQEFYDPMVASGQKREMGAALFTGW    mkh-Cldn1-4-1(D)  low *  Kimura et al., 2009 [44] 
WYGNRIVQEFYNPMTPVNARYEFGQALFTGW    hu-D150N  +  Robertson et al., 2009 [62] 
WNLHGILRDFYSPLVPDSMKFEIGEALYLGI  2  wt  - (L)  Winkler et al., 2009 [37] 
WNLHGILRDFYSPLVPDSMKFEIGEALYLGI    Cldn2  low *  Kimura et al., 2009 [44] 
WNLHGILRDFYNPLVPDSMKFEIGEALYLGI    S149N  high  Winkler et al., 2009 [37] 
WNLHGILRDFYNPLVPDSMKFEIGEALYLGI    hu-S149N  +  Robertson et al., 2009 [62] 
WNLHGILRDFYNPLVPDAMKFEIGEALYLGI    S149N/S155A  high (L)  Winkler et al., 2009 [37] 
WNLHGILRDFYNPLVPDAMKREIGEALYLGI    S149N/S155A/F158R  high (L)  Winkler et al., 2009 [37] 
WNLHGILRDFYSPLVPDSMKFEIGEALYLGI    hu-Claudin-2  -  Robertson et al., 2009 [62] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    hu-Claudin-2/E4  +  Robertson et al., 2009 [62] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    hu-Claudin-2/E4  +  Robertson et al., 2009 [62] 
WNLHGILRDFYSPLVPDSMKFEIGEALYLGI    hu-Claudin-2 108-230  -  Robertson et al., 2009 [62] 
WNLHGILRDFYSPLVPDSMKFEIGEALYLGI    hu-Claudin-2 136-230  -  Robertson et al., 2009 [62] Toxins 2010, 2                               
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Table 1. Cont. 
ECL2-sequence  Claudin  construct  Binding capacity  source 
WSANTIIRDFYNPLVPEAQKREMGAGLYVGW  3  wt  high (L)  Winkler et al., 2009 [37] 
WSANTIIRDFYNPLVPEAQKREMGAGLYVGW    msCldn3  high *  Kimura et al., 2009 [44] 
WSANTIIRDFANPLVPEAQKREMGAGLYVGW    Y147A  high (higher than wt) (L)  Winkler et al., 2009 [37] 
WSANTIIRDFYDPLVPEAQKREMGAGLYVGW    N148D  - (L)  Winkler et al., 2009 [37] 
WSANTIIRDFYDPLVPEAQKREMGAGLYVGW    N148D  high  Winkler et al., 2009 [37] 
WSANTIIRDFYDPAVPEAQKREMGAGLYVGW    N148D/L150A  -  Winkler et al., 2009 [37] 
WSANTIIRDFYNPAVPEAQKREMGAGLYVGW    L150A  - (L)  Winkler et al., 2009 [37] 
WSANTIIRDFYNPLVPVAQKREMGAGLYVGW    E153V  medium (L)  Winkler et al., 2009 [37] 
WSANTIIRDFYNPLVPENQKREMGAGLYVGW    A154N  medium (L)  Winkler et al., 2009 [37] 
WSANTIIRDFYNPLVPEAEKREMGAGLYVGW    Q155E  high (L)  Winkler et al., 2009 [37] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW  4  wt  - (L)  Winkler et al., 2009 [37] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    hu-wt  +  Robertson et al., 2009 [62] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    hu-wt  +  Robertson et al., 2009 [62] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    wt  high (p)  Ling et al., 2008 [58] 
WTAHNVIRDFYNPMVPSGQKREMGASLYVGW    A153P  - (L)  Winkler et al., 2009 [37] 
WTAHNVIRDFYNPLVPSGQKREMGASLYVGW    M151L/A153P  medium (L)  Winkler et al., 2009 [37] 
WNLHGILRDFYSPLVPDSMKFEIGEALYLGI    hu-Claudin-4/E2  -  Robertson et al., 2009 [62] 
WNLHGILRDFYSPLVPDSMKFEIGEALYLGI    hu-Claudin-4/E2  -  Robertson et al., 2009 [62] 
WTAHNIIQDFYNPLVASGQKREMGASLYVGW    hu-Claudin-4 108-209  +  Robertson et al., 2009 [62] 
WTAHNIIQDFYNPLVASGQKREMGASLYVGW    hu-Claudin-4 136-209  +  Robertson et al., 2009 [62] 
WTAHNIIQDFYSPLVASGQKREMGASLYVGW    hu-N149S  -  Robertson et al., 2009 [62] 
WTAHNIIQDFYSPLVASGQKREMGASLYVGW    hu-N149S  -  Robertson et al., 2009 [62] 
WTAHNIIQDFYDPLVASGQKREMGASLYVGW    hu-N149D  -  Robertson et al., 2009 [62] 
WTAHNIIQDFYDPLVASGQKREMGASLYVGW    hu-N149D  -  Robertson et al., 2009 [62] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    Ecl 2  medium (p)  Ling et al., 2008 [58] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    TM3.Ecl2.TM4  high (p)  Ling et al., 2008 [58] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    TM3.Ecl2.CT  high (p)  Ling et al., 2008 [58] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    Ecl2.CT  high (higher than wt) (p)  Ling et al., 2008 [58] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    Cldn4  high *  Kimura et al., 2009 [44] 
WTAHNIIQDFYNPLVASGQKREMGASLYVGW    hu-Cldn4  hight *  Kimura et al., 2009 [44] 
WTAHNVIRDFYNPMVASGQKREMGASLYVGW    mk-Cldn4  high *  Kimura et al., 2009 [44] 
WTAHNIIQDFYNPLVASGQKREFGQALFTGW    mkh-Cldn4-1(A)  insensitive *  Kimura et al., 2009 [44] 
WTAHNIIQDFYNPLVASGQKREMGQALFTGW    mkh-Cldn4-1(B)  high *  Kimura et al., 2009 [44] 
WTAHNIIQDFYNPLVASGQKREMGAALFTGW    mkh-Cldn4-1( C)  high *  Kimura et al., 2009 [44] 
WTAHNVIRDFYDPSVPVSQKYELGASLYVGW    hu-Cldn4-5-4  insensitive *  Kimura et al., 2009 [44] 
WTAHNIIQDFYDPLVASGQKYEMGASLYVGW    hu-Cldn4NRDY  low *  Kimura et al., 2009 [44] 
WFANIVVREFYDPTVPVSQKYELGAALYIGW  5  wt  - (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVSQKYELGAALYIGW    wt  -  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVSQKYELGAALYIGW    wt  low (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVSQKYELGAALYIGW    Cldn5  insensitive *  Kimura et al., 2009 [44] 
WFANIVVREFYDPTVPVSQKYELGAALYIGW    hu-Cldn5  insensitive *  Kimura et al., 2009 [44] 
WFANIVVREFYNPLVASGQKREMGAALYIGW    hu-Cldn5-4-5  high *  Kimura et al., 2009 [44] Toxins 2010, 2                               
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Table 1. Cont. 
ECL2-sequence  Claudin  construct  Binding capacity  source 
WFANIVVREFYNPLTPMNVKYEFGAALYIGW    muh-Cldn5-7-5  high *  Kimura et al., 2009 [44] 
WFANIVVREFYNPSVPVSQKRELGAALYIGW    hu-Cldn5DYNR  low *  Kimura et al., 2009 [44] 
WFANIVVAEFYDPTVPVSQKYELGAALYIGW    R145A  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVQEFYDPTVPVSQKYELGAALYIGW    R145Q  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVRNFYDPTVPVSQKYELGAALYIGW    E146N  low (wt) (L)  Winkler et al., 2009 [37] 
WFANIVVRDFYDPTVPVSQKYELGAALYIGW    E146D  - (L)  Winkler et al., 2009 [37] 
WFANIVVRDFYDPTVPVAQKYELGAALYIGW    E146D/S155A  - (L)  Winkler et al., 2009 [37] 
WFANIVVRDFYDPTVPVAQKRELGAALYIGW    E146D/S155A/Y158R  - (L)  Winkler et al., 2009 [37] 
WFANIVVRDFYDPLVPEAQKRELGAALYIGW    E146D/T151L/V154E/S155A/Y158R  - (L)  Winkler et al., 2009 [37] 
WFANIVVRDFYNPLVPEAQKYELGAALYIGW    E146D/D149N/T151L/V154E/S155A  high (L)  Winkler et al., 2009 [37] 
WFANIVVREAYDPTVPVSQKYELGAALYIGW    F147A  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVREFADPTVPVSQKYELGAALYIGW    Y148A  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVREFYNPTVPVSQKYELGAALYIGW    D149N  - (L)  Winkler et al., 2009 [37] 
WFANIVVREFYNPTVPVSQKYELGAALYIGW    D149N  low (L)  Winkler et al., 2009 [37] 
WFANIVVREFYNPLVPVSQKYELGAALYIGW    D149N/T151L  medium (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDATVPVSQKYELGAALYIGW    P150A  low (lower than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPAVPVSQKYELGAALYIGW    T151A  - (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPLVPVSQKYELGAALYIGW    T151L  - (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPASQKYELGAALYIGW    V154A  low (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPESQKYELGAALYIGW    V154E  - (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVAQKYELGAALYIGW    S155A  - (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVAQKYELGAALYIGW    S155A  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVSAKYELGAALYIGW    Q156A  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVSEKYELGAALYIGW    Q156E  - (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVSQKAELGAALYIGW    Y158A  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WFANIVVREFYDPTVPVSQKYQLGAALYIGW    E159Q  low (higher than wt) (L)  Winkler et al., 2009 [37] 
WTAHSIIQDFYNPLVADAQKRELGASLYLGW  6  wt  high (L)  Winkler et al., 2009 [37] 
WIGHQIVTDFYNPLTPMNVKYEFGPAIFIGW  7  wt  medium (L)  Winkler et al., 2009 [37] 
WIGHQIVTDFYNPLTPMNVKYEFGPAIFIGW    Cldn7  high *  Kimura et al., 2009 [44] 
WIGHQIVTDFYDPSVPVSQKYELGPAIFIGW    muh-Cldn7-5-7  insensitive *  Kimura et al., 2009 [44] 
WVANSIIRDFYNPLVDVALKRELGEALYIGW  8  wt  - (L)  Winkler et al., 2009 [37] 
WVANSIIRDFYNPLVDVALKRELGEALYIGW    Cldn8  high *  Kimura et al., 2009 [44] 
WTAHAIIQDFYNPLVAEALKRELGASLYLGW  9  wt  high (L)  Winkler et al., 2009 [37] 
LYANKITTEFFDPLYME-QKYELGAALFIGW  10  wt  - (L)  Winkler et al., 2009 [37] 
LYANKITTEFFDPLFVE-QKYELGAALFIGW    hu-Cldn10  insensitive *  Kimura et al., 2009 [44] 
WFPVCAHREITIVSF--------GYSLYAGW  11  wt  - (L)  Winkler et al., 2009 [37] 
WAIFYNSHLNRKFEPVFTFDYAVFVTIASSG  12  wt  - (L)  Winkler et al., 2009 [37] 
WVTHNIIHGFFNPLLGFSKKVQMGSSLSLAW  13  wt  - (L)  Winkler et al., 2009 [37] 
WTTNDVVQNFYNPLLPSGMKFEIGQALYLGF  14  wt  medium (L)  Winkler et al., 2009 [37] 
WTTNDVVQNFYNPLLPSGMKFEIGQALYLGF    Cldn14  low *  Kimura et al., 2009 [44] 
  15-22  wt  - (L)  Winkler et al., 2009 [37] Toxins 2010, 2                               
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In addition, Kimura et al.  reported that a  Cld4/Cld1 chimera bound to cCPE as long as they 
contained the particular residue M160 from Cld4 at the end of ECL2, but not the corresponding F161 from 
Cld1 [44].  In another study, substitution mapping of Cld3-ECL2 peptides [37] suggested that this 
methionine, which is conserved between Cld4 and Cld3, is rather not directly involved in interaction 
with CPE. Alternatively, it could change the structure, especially at the transition between ECL2 and 
the 4th
 transmembrane segment (TM4) of Cld3/-4 compared to Cld1 and, therefore, play a role in  
CPE-binding. Results from SRP measurements using recombinant Cld4 protein as analyte are in line 
with this interpretation. So it was found that CPE290–319  binds much stronger to Cld4-constructs 
containing the TM4 in addition to the ECL2 than the ECL2 alone [58]. Similarly, a recombinant Cld4 
construct containing ECL2 and TM4 was able to compete for binding of full length CPE in cellular 
binding assays [62].  
Aromatic amino acids in CPE (Y306, Y310 and Y312) are involved in the binding to claudins [60] 
and aromatic residues in the ECL2 of classic claudin are crucial for trans-interaction between each 
other [54]. It was discussed that the aromatic residues in claudin could also interact with the aromatic 
amino acids in CPE [58]. But removal of aromatic residues in the ECL2 of Cld3, Cld4 or Cld5 
(binding to CPE116–319) did not reduce the ability of CPE to bind to its receptors [37,44]. Moreover, in a 
preliminary model, the aromatic residues in the ECL2 do rather not sterically match the aromatic 
residues in CPE (Figure 1b and [37]). Taken together, the published data (summarized in Table 1) 
indicate that residues in the turn region of the loop, but not aromatic residues in the flanking helices, 
are involved in the claudin-CPE interaction. Residues in the C-terminal flank of the loop and in the 
following TM4 could contribute to the interaction with CPE either by direct interaction or by 
determining the structural conformation of the loop.  
It was observed that cCPE binds preferentially to claudin molecules outside of tight junction 
strands [37]. This is consistent with the idea that CPE sequesters claudins in the plasma membrane, 
preventing their incorporation in TJ strands. Such a sequestering mechanism could explain the long 
incubation time with cCPE needed for the opening of TJ, despite the high affinity of cCPE to claudins [43].  
6. Potential Pharmacological Use of Clostridium perfringens Enterotoxin  
6.1. cCPE as a TJ-Modulator 
Many  promising drug candidates  cannot be used clinically because of unacceptable 
pharmacokinetics. The competence to cross tissue barriers is a major determinant for the delivery of a 
drug to its target. Several approaches have been used to enhance transcellular drug delivery, including 
utilization  of  endogenous  influx  transporters, blocking of the barrier supporting activity of efflux 
transporters, or receptor-mediated  transcytosis  [68].  An alternative  strategy  tries to enhance 
paracellular permeation of drugs by transient opening of the TJ [69,70]. The strength of this approach 
is (i) the improvement of the delivery of structurally unrelated drugs and (ii) that the drug itself does 
not have to be  modified.  Most of the different TJ modulators, described within last years, have 
surfactant- or chelator-like characteristics. They are often compromised by low tissue specificity and 
severe side effects, e.g.,  exfoliation of cells, which irreversibly  compromise  the barrier functions 
[71,72]. It was suggested that fewer side effects may be obtained by more specific modulation of a Toxins 2010, 2                               
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molecular key component of the TJ [73]. cCPE is a promising tool to modulate TJ in a direct and 
tissue-specific manner: (1) It binds with high affinity to claudins that are essential for TJ formation.  
(2)  CPE  binds to a subset of claudins, only. This restricts its activity to tissues that express   
CPE-sensitive claudins. (3) It is able to increase the paracellular permeability in a reversible and 
concentration-dependent manner. (4) cCPE enhances drug absorption in rat jejunum 400-fold relative 
to sodium caprate, which is in clinical use [5]. In addition,  cCPE is known to enable mucosal 
absorption of a biologically active peptide [65]. Cld1 and Cld5 are potential targets for transepidermal 
and brain drug delivery, respectively [74,75]. However, it has been reported that these claudins do not 
strongly interact with CPE [43]. Alternatively, Cld3 could be considered to improve the brain uptake. 
Moreover, modification of cCPE could shift its claudin-subtype specificity to enable drug delivery to 
the brain. 
6.2. Treatment of tumors overexpressing claudins by cCPE-constructs 
Several studies have suggested the use of CPE for the chemotherapy of tumors overexpressing 
claudins [76–78]. The CPE-receptors Cld3 and Cld4 are strongly upregulated in many pancreatic, 
ovarian, breast and uterine cancers [76,79]. The use of other surface proteins for targeting cancer cells 
has been already demonstrated. For instance, ligands for cytokine- and growth factor receptors have 
been fused with fragments of bacterial toxins, such as diphtheria toxin and Pseudomonas exotoxin 
[80,81]. Similarly, fusion proteins of diphtheria toxin fragment A and cCPE were generated to target 
Cld4-overexpressing tumor cells [82]. CPE-fragments fused to tumor necrosis factor effected human 
ovarian cancer cells [83]. Injections of full length and hence cytotoxic CPE into pancreatic tumors in 
mice resulted in tumor necrosis and reduction  of tumor growth [84]. Human ovarian cancer cells 
transplanted in mice  could be also eliminated by injection of CPE  [85].  Intracranial CPE 
administration  reduced  growth  of  breast cancer brain metastasis and increased survival in murine 
models [76]. Recently, cCPE fusion proteins were successfully used for nasal vaccination, a strategy 
that could be used for different therapeutic approaches including tumor treatment [82].These studies 
demonstrated the therapeutic potential of CPE-constructs. 
7. Conclusions and Remarks 
In the last decade tremendous progress has been made in the characterization of the structure and 
function of CPE and its receptors, the claudins. Of particular importance is the solved crystal structure 
of the claudin-binding domain of CPE and recent advances in identification of residues in CPE and 
claudins that are involved in the interaction between each other. Claudins are highly relevant for tissue 
barriers, tumor growth and, as recently discovered, hepatitis virus C infection [86]. CPE has already 
successfully been applied to target claudins for therapeutic approaches in animal models. Hence, future 
progress in the molecular understanding of the CPE-claudin interaction may facilitate the development 
of improved recombinant cCPE proteins  and cCPE-based peptidomimetics as powerful 
pharmacological tools. Toxins 2010, 2                               
 
 
1350 
Figure 1. (a) Homologous helix-turn-helix model of the ECL2 of mouse Cld3 based on the 
fragment of PDB code 2BDV in front view. Residues F146 to R157 and M160 are shown 
(ball and stick), key residues for CPE-claudin interaction N148 and L150 [37] are given in 
red. M160 (green) was also reported to be involved in CPE-claudin interaction [44]. 
Residues F146, Y147 (grey), and R157 (blue) correspond to aromatic residues F147, Y148, 
and Y158 in Cld5, which were found to be important for trans–interaction. Heteroatoms 
are red (oxygen), dark blue (nitrogen), white (hydrogen), and yellow (sulfur). Black dashed 
lines: hydrogen bonds, grey dashed line: cell-membrane. (b) Supposed spatial regions of 
interaction between binding sensitive residues (Y306, Y310, Y312, and L315 from 
literature  [60]) visualized at the CPE194–319 x-ray structure (PDB code 2QUO) and 
residues (148NPLVP, Q155) in Cld3. Key-residues for the CPE-claudin interaction are 
highlighted in red. 
 
References 
1.  McClane, B.A.  The complex interactions between Clostridium perfringens enterotoxin and 
epithelial tight junctions. Toxicon 2001, 39, 1781–1791. 
2.  Smedley,  J.G.,  III;  McClane,  B.A.  Fine mapping of the N-terminal cytotoxicity region of 
Clostridium perfringens enterotoxin by site-directed mutagenesis. Infect. Immun.  2004,  72, 
6914–6923. Toxins 2010, 2                               
 
 
1351 
3.  Miyakawa, M.E.F.; Creydt, V.P.; Uzal, F.A.; McClane, B.A.; Ibarra, C. Clostridium perfringens 
enterotoxin damages the human intestine in vitro. Infect. Immun. 2005, 73, 8407–8410. 
4.  Sonoda, N.; Furuse, M.; Sasaki, H.; Yonemura, S.; Katahira, J.; Horiguchi, Y.;  Tsukita,  S. 
Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction 
strands: Evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol. 1999, 
147, 195–204. 
5.  Kondoh, M.; Masuyama, A.; Takahashi, A.; Asano, N.; Mizuguchi, H.; Koizumi, N.; Fujii, M.; 
Hayakawa, T.; Horiguchi, Y.; Watanbe,  Y.  A novel strategy for the enhancement of drug 
absorption using a claudin modulator. Mol. Pharmacol. 2005, 67, 749–756. 
6.  Rood, J.I. Virulence genes of Clostridium perfringens. Annu. Rev. Microbiol. 1998, 52, 333–360. 
7.  Sakurai, J.; Nagahama, M.; Oda, M. Clostridium perfringens alpha-toxin: Characterization and 
mode of action. J. Biochem. 2004, 136, 569–574. 
8.  Awad, M.M.; Ellemor, D.M.; Boyd, R.L.; Emmins, J.J.; Rood, J.I. Synergistic effects of alpha-
toxin and perfringolysin O in Clostridium perfringens-mediated gas gangrene. Infect. Immun. 
2001, 69, 7904–7910. 
9.  Nagahama, M.; Hayashi, S.; Morimitsu, S.; Sakurai, J. Biological activities and pore formation of 
Clostridium perfringens beta toxin in HL 60 cells. J. Biol. Chem. 2003, 278, 36934–36941. 
10.  Fisher, D.J.; Fernandez-Miyakawa, M.E.; Sayeed, S.; Poon, R.; Adams, V.; Rood, J.I.; Uzal, F.A.; 
McClane, B.A. Dissecting the contributions of Clostridium perfringens type C toxins to lethality 
in the mouse intravenous injection model. Infect. Immun. 2006, 74, 5200–5210. 
11.  Miyata, S.; Minami, J.; Tamai, E.; Matsushita, O.; Shimamoto, S.; Okabe,  A.  Clostridium 
perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of 
Madin-Darby canine kidney cells and rat synaptosomes. J. Biol. Chem. 2002, 277, 39463–39468. 
12.  Petit, L.;  Gibert,  M.; Gourch, A.; Bens, M.; Vandewalle, A.;  Popoff,  M.R.  Clostridium 
perfringens epsilon toxin rapidly decreases membrane barrier permeability of polarized MDCK 
cells. Cell. Microbiol. 2003, 5, 155–164. 
13.  Petit, L.; Maier, E.; Gibert, M.; Popoff, M.R.; Benz, R. Clostridium perfringens epsilon toxin 
induces a rapid change of cell membrane permeability to ions and forms channels in artificial lipid 
bilayers. J. Biol. Chem. 2001, 276, 15736–15740. 
14.  Loffler, A.; Labbe, R.G. Isolation of An Inclusion Body from Sporulating, Enterotoxin-Positive 
Clostridium-Perfringens. FEMS Microbiol. Lett. 1985, 27, 143–147. 
15.  Loffler,  A.; Labbe, R. Characterization of A Parasporal Inclusion Body from Sporulating, 
Enterotoxin-Positive Clostridium-Perfringens Type-A. J. Bacteriol. 1986, 165, 542–548. 
16.  Duncan, C.L.; Sugiyama, H.; Strong, D.H. Rabbit Ileal Loop Response to Strains of Clostridium 
Perfringens. J. Bacteriol. 1968, 95, 1560–1566. 
17.  Strong,  D.H.;  Duncan,  C.L.;  Perna,  G.  Clostridium-Perfringens Type-A  Food Poisoning.  2. 
Response of Rabbit Ileum As An Indication of Enteropathogenicity of Strains of Clostridium-
Perfringens in Human Beings. Infect. Immun. 1971, 3, 171–178. 
18.  Niilo, L. Fluid Secretory Response of Bovine Thiry Jejunal Fistula to Enterotoxin of Clostridium-
Perfringens. Infect. Immun. 1973, 7, 1–4. 
19.  Skjelkvale,  R.;  Uemura,  T.  Experimental Diarrhea in Human Volunteers Following Oral-
Administration of Clostridium-Perfringens Enterotoxin. J. Appl. Bacteriol. 1977, 43, 281–286. Toxins 2010, 2                               
 
 
1352 
20.  Sarker, R.; Carman, R.J.; McClane, B.A. Inactivation of the gene (cpe) encoding Clostridium 
perfringens enterotoxin eliminates the ability of two cpe-positive C-perfringens type A human 
gastrointestinal disease isolates to affect rabbit ileal loops. Mol. Microbiol. 1999, 33, 946–958. 
21.  Czeczulin, J.R.; Hanna, P.C.; McClane, B.A. Cloning, Nucleotide Sequencing, and Expression of 
the Clostridium-Perfringens Enterotoxin Gene in Escherichia-Coli.  Infect. Immun. 1993,  61, 
3429–3439. 
22.  Fujinaga, Y.; Inoue, K.; Shimazaki, S.; Tomochika, K.; Tsuzuki, K.; Fujii, N.; Watanabe, T.; 
Ohyama,  T.; Takeshi, K.; Inoue, K.;  Oguma,  K.  Molecular Construction of Clostridium-
Botulinum Type-C Progenitor Toxin and Its Gene Organization. Biochem. Biophys. Res. Commun. 
1994, 205, 1291–1298. 
23.  Sherman, S.; Klein, E.;  McClane,  B.A.  Clostridium-Perfringens Type-A Enterotoxin Induces 
Tissue-Damage and Fluid Accumulation in Rabbit Ileum. J. Diarrhoeal Dis. Res. 1994, 12, 
200–207. 
24.  McDonel,  J.L.;  Chang,  L.W.;  Pounds,  J.G.;  Duncan,  C.L.  Effects of Clostridium-Perfringens 
Enterotoxin on Rat and Rabbit Ileum - Electron-Microscopic Study. Lab. Invest. 1978, 39, 210–218. 
25.  Singh, U.;  Mitic,  L.L.;  Wieckowski,  E.U.;  Anderson,  J.M.;  McClane,  B.A.  Comparative 
biochemical and immunocytochemical studies reveal differences in the effects of Clostridium 
perfringens enterotoxin on polarized CaCo-2 cells versus Vero cells. J. Biol. Chem. 2001, 276, 
33402–33412. 
26.  Matsuda, M.; Sugimoto, N. Calcium-Independent and Dependent Steps in Action of Clostridium-
Perfringens Enterotoxin on Hela and Vero Cells. Biochem. Biophys. Res. Commun. 1979, 91, 
629–636. 
27. McClane, B.A.; McDonel, J.L. The effects of Clostridium perfringens enterotoxin on morphology, 
viability, and macromolecular synthesis in Vero cells. J. Cell Physiol. 1979, 99, 191–200. 
28.  Katahira, J., Sugiyama, H.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Clostridium 
perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors 
in vivo. J. Biol. Chem. 1997, 272, 26652–26658. 
29. Robertson, S.L.; Smedley, J.G., III.; Singh, U.; Chakrabarti, G.; Van Itallie, C.M.; Anderson, J.M.; 
McClane, B.A. Compositional and stoichiometric analysis of Clostridium perfringens enterotoxin 
complexes in Caco-2 cells and claudin 4 fibroblast transfectants. Cell Microbiol.  2007,  9, 
2734–2755. 
30.  Wieckowski,  E.U.;  Wnek,  A.P.;  McClane,  B.A.  Evidence That An Approximate-To-50-Kda 
Mammalian Plasma-Membrane Protein with Receptor-Like Properties Mediates the 
Amphiphilicity of Specifically Bound Clostridium-Perfringens Enterotoxin. J. Biol. Chem. 1994, 
269, 10838–10848. 
31.  Wieckowski,  E.U.;  Kokai-Kun,  J.F.;  McClane,  B.A.  Characterization of membrane-associated 
Clostridium perfringens enterotoxin following pronase treatment. Infect.  Immun.  1998,  66, 
5897–5905. 
32.  Smedley, J.G.; Uzal, F.A.; McClane, B.A. Identification of a prepore large-complex stage in the 
mechanism of action of Clostridium perfringens enterotoxin. Infect. Immun. 2007, 75, 2381–2390. Toxins 2010, 2                               
 
 
1353 
33.  Chakrabarti, G.; McClane, B.A. The importance of calcium influx, calpain and calmodulin for the 
activation of CaCo-2 cell death pathways by Clostridium perfringens enterotoxin. Cell. Microbiol. 
2005, 7, 129–146. 
34.  Kokai-Kun, J.F.; McClane, B.A. Deletion analysis of the Clostridium perfringens enterotoxin. 
Infect. Immun. 1997, 65, 1014–1022. 
35.  Kokai-Kun, J.F.; Benton, K., Wieckowski, E.U., McClane, B.A. Identification of a Clostridium 
perfringens enterotoxin region required for large complex formation and cytotoxicity by random 
mutagenesis. Infect. Immun. 1999, 67, 5634–5641. 
36.  Hanna,  P.C.;  Mietzner,  T.A.;  Schoolnik,  G.K.;  McClane,  B.A.  Localization of the receptor-
binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and 
synthetic peptides. The 30 C-terminal amino acids define a functional binding region. J. Biol. 
Chem. 1991, 266, 11037–11043. 
37.  Winkler, L.; Gehring, C.; Wenzel, A.; Muller, S.L.; Piehl, C.; Krause, G.; Blasig, I.E.; Piontek, J. 
Molecular Determinants of the Interaction between Clostridium perfringens Enterotoxin 
Fragments and Claudin-3. J. Biol. Chem. 2009, 284, 18863–18872. 
38.  Van Itallie,  C.M.; Betts, L.;  Smedley,  J.G.;  McClane,  B.A.;  Anderson,  J.M.  Structure of the 
claudin-binding domain of Clostridium perfringens enterotoxin. J. Biol. Chem. 2008, 283, 268–274. 
39.  Wilson, J.J.; Matsushita, O.; Okabe, A.; Sakon, J. A bacterial collagen-binding domain with novel 
calcium-binding motif controls domain orientation. EMBO J. 2003, 22, 1743–1752. 
40.  Boonserm,  P.; Davis, P.;  Ellar,  D.J.;  Li,  J.  Crystal structure of the mosquito-iarvicidal toxin 
Cry4Ba and its biological implications. J. Mol. Biol. 2005, 348, 363–382. 
41.  Katahira, J.; Inoue, N.;  Horiguchi,  Y.; Matsuda, M.;  Sugimoto,  N.  Molecular cloning and 
functional characterization of the receptor for Clostridium perfringens enterotoxin. J. Cell Biol. 
1997, 136, 1239–1247. 
42.  Morita, K.; Furuse, M.; Fujimoto, K.;  Tsukita,  S.  Claudin multigene family encoding four-
transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. USA 
1999, 96, 511–516. 
43.  Fujita, K.; Katahira, J.;  Horiguchi,  Y.; Sonoda, N.; Furuse, M.;  Tsukita,  S.  Clostridium 
perfringens  enterotoxin binds to the second extracellular loop of claudin-3, a tight junction 
integral membrane protein. FEBS Lett. 2000, 476, 258–261. 
44.  Kimura, J.; Abe, H.; Kamitani, S.; Toshima, H.; Fukui, A.; Miyake, M.; Kamata, Y.; Sugita-
Konishi, Y.; Yamamoto, S., Horiguchi, Y. Clostridium perfringens Enterotoxin Interacts with 
Claudins via Electrostatic Attraction. J. Biol. Chem. 2010, 285, 401–408. 
45.  Krause, G.; Winkler, L.; Mueller, S.L.; Haseloff, R.F.; Piontek, J.; Blasig,  I.E. Structure and 
function of claudins. Biochim. Biophys. Acta 2008, 1778, 631–645. 
46.  Staehelin, L.A. Structure and function of intercellular junctions. Int. Rev. Cytol. 1974, 39, 191–283. 
47.  Furuse, M.; Hirase, T.; Itoh, M.; Nagafuchi, A.; Yonemura, S.; Tsukita, S.; Tsukita, S. Occludin: a 
novel integral membrane protein localizing at tight junctions. J. Cell Biol. 1993, 123, 1777–1788. 
48.  Ikenouchi, J.; Furuse, M.; Furuse, K.; Sasaki, H.; Tsukita, S.; Tsukita, S. Tricellulin constitutes a 
novel barrier at tricellular contacts of epithelial cells. J. Cell Biol. 2005, 171, 939–945. 
49.  Steed, E.; Rodrigues, N.T.; Balda, M.S.; Matter, K. Identification of MarvelD3 as a tight junction-
associated transmembrane protein of the occludin family. BMC Cell Biol. 2009, 10, 95. Toxins 2010, 2                               
 
 
1354 
50.  Gonzalez-Mariscal, L.; Betanzos, A.; Nava, P.; Jaramillo, B.E. Tight junction proteins. Prog. 
Biophys. Mol. Biol. 2003, 81, 1–44. 
51. Umeda, K.; Ikenouchi, J.; Katahira-Tayama, S.; Furuse, K.; Sasaki, H.; Nakayama, M.; Matsui, T.; 
Tsukita, S.; Furuse, M.; Tsukita, S. ZO-1 and ZO-2 independently determine where claudins are 
polymerized in tight-junction strand formation. Cell 2006, 126, 741–754. 
52.  Yu, A.S.; Cheng, M.H.; Angelow, S.; Gunzel, D.; Kanzawa, S.A.; Schneeberger, E.E.; Fromm, 
M.; Coalson, R.D. Molecular basis for cation selectivity in claudin-2-based paracellular pores: 
identification of an electrostatic interaction site. J. Gen. Physiol. 2009, 133, 111–127. 
54.  Daugherty, B.L.; Ward, C.; Smith, T.; Ritzenthaler, J.D.; Koval, M. Regulation of heterotypic 
claudin compatibility. J. Biol. Chem. 2007, 282, 30005–30013. 
54.  Piontek, J.; Winkler, L.; Wolburg, H.; Muller, S.L.; Zuleger, N.; Piehl, C.; Wiesner, B.; Krause, 
G.;  Blasig,  I.E.  Formation of tight junction: determinants of homophilic interaction between 
classic claudins. FASEB J. 2008, 22, 146–158. 
55.  Zhang, J.; Piontek, J.; Wolburg, H.; Piehl, C.; Liss, M.; Otten, C.; Christ, A.; Willnow, T.E.; 
Blasig, I.E.; Abdelilah-Seyfried, S. Establishment of a neuroepithelial barrier by Claudin5a is 
essential for zebrafish brain ventricular lumen expansion. Proc. Natl. Acad. Sci. USA 2010, 107, 
1425–1430. 
56.  Piehl,  C.;  Piontek,  J.;  Cording,  J.;  Wolburg,  H.;  Blasig,  I.E.  Participation of the second 
extracellular loop of claudin-5 in paracellular tightening against ions, small and large molecules. 
Cell Mol. Life Sci. 2010, doi:10.1007/s00018-010-0332-8. 
57.  Krause, G.; Winkler, L.; Piehl, C.; Blasig, I.; Piontek, J.; Muller, S.L. Structure and Function of 
Extracellular Claudin Domains. Ann. N.Y. Acad. Sci. 2009, 1165, 34–43. 
58.  Ling, J.; Liao, H.; Clark, R.; Wong, M.S.; Lo, D.D. Structural constraints for the binding of short 
peptides to claudin-4 revealed by surface plasmon resonance. J. Biol. Chem.  2008,  283, 
30585–30595. 
59.  Harada, M.; Kondoh, M.; Ebihara, C.; Takahashi, A.; Komiya, E.; Fujii, M.; Mizuguchi, H.; 
Tsunoda, S.; Horiguchi, Y.; Yagi, K.; Watanabe, Y. Role of tyrosine residues in modulation of 
claudin-4 by the C-terminal fragment of Clostridium perfringens enterotoxin.  Biochem. 
Pharmacol. 2007, 73, 206–214. 
60.  Takahashi, A.; Komiya, E.; Kakutani, H.; Yoshida, T.; Fujii, M.; Horiguchi, Y.; Mizuquchi, H.; 
Tsutsumi, Y.;  Tsunoda,  S.I.; Koizumi, N.; Isoda, K.; Yagi, K.; Watanabe, Y.;  Kondoh,  M. 
Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of 
Clostridium perfringens enterotoxin, by site-directed mutagenesis. Biochem. Pharmacol. 2008, 75, 
1639–1648. 
61.  Lohrberg, D.; Krause, E.; Schumann, M.; Piontek, J.; Winkler, L.; Blasig, I.E.; Haseloff, R.F. A 
strategy for enrichment of claudins based on their affinity to Clostridium perfringens enterotoxin. 
BMC Cell Biol. 2009, 10, 61. 
62.  Robertson, S.L.; Smedley, J.G.; McClane, B.A. Identification of a Claudin-4 Residue Important 
for Mediating the Host Cell Binding and Action of Clostridium perfringens Enterotoxin. Infect. 
Immun. 2010, 78, 505–517. Toxins 2010, 2                               
 
 
1355 
63.  Ebihara, C.; Kondoh,  M.; Hasuike, N.; Harada, M.; Mizuguchi, H.; Horiguchi, Y.; Fujii, M.; 
Watanabe,  Y.  Preparation of a claudin-targeting molecule using a C-terminal fragment of 
Clostridium perfringens enterotoxin. J. Pharmacol. Exp. Ther. 2006, 316, 255–260. 
64.  Swisshelm K,.; Machl, A.; Planitzer, S.; Robertson, R.; Kubbies, M.;  Hosier,  S.  SEMP1, a 
senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an 
epithelial membrane protein superfamily. Gene 1999, 226, 285–295. 
65.  Uchida, H.; Kondoh, M.; Hanada, T.; Takahashi, A.; Hamakubo, T.;  Yagi,  K.  A claudin-4 
modulator enhances the mucosal absorption of a biologically active peptide. Biochem. Pharmacol. 
2010, 79, 1437–1444. 
66.  Ebihara, C.; Kondoh, M.; Harada, M.; Fujii, M.; Mizuguchi, H.; Tsunoda, S.; Horiguchi, Y.; Yagi, 
K.;  Watanabe,  Y.  Role of Tyr306 in the C-terminal fragment of Clostridium perfringens 
enterotoxin for modulation of tight junction. Biochem. Pharmacol. 2007, 73, 824–830. 
67.  Takahashi, A.; Kondoh, M.; Masuyama, A.; Fujii, M.; Mizuguchi, H.; Horiguchi, Y.; Watanabe, 
Y. Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin 
in its interaction with claudin-4. J. Control. Release 2005, 108, 56–62. 
68.  Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug 
discovery and development. Pharmacol. Rev. 2003, 55, 425–461. 
69.  Aungst, B.J. Intestinal permeation enhancers. J. Pharm. Sci. 2000, 89, 429–442. 
70.  Salama, N.N.; Eddington, N.D.; Fasano, A. Tight junction modulation and its relationship to drug 
delivery. Adv. Drug Delivery Rev. 2006, 58, 15–28. 
71.  Hochman,  J.;  Artursson,  P.  Mechanisms of Absorption Enhancement and Tight Junction 
Regulation. J. Controlled Release 1994, 29, 253–267. 
72.  Yamamoto, A.; Uchiyama, T.; Nishikawa, R.; Fujita, T.; Muranishi, S. Effectiveness and toxicity 
screening of various absorption enhancers in the rat small intestine: Effects of absorption 
enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids 
from the intestinal membrane. J. Pharm. Pharmacol. 1996, 48, 1285–1289. 
73.  Kondoh, M.; Takahashi, A.; Fujii, M.; Yagi, K.;  Watanabe,  Y.  A novel strategy for a drug 
delivery system using a claudin modulator. Biol. Pharm. Bull. 2006, 29, 1783–1789. 
74.  Furuse, M.; Hata, M.; Furuse, K.; Yoshida, Y.; Haratake, A.; Sugitani, Y.; Noda, T.; Kubo, A.; 
Tsukita,  S.  Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a 
lesson from claudin-1-deficient mice. J. Cell Biol. 2002, 156, 1099–1111. 
75.  Nitta, T.; Hata, M.; Gotoh, S.; Seo, Y.; Sasaki, H.; Hashimoto, N.; Furuse, M.; Tsukita, S. Size-
selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 2003, 161, 
653–660. 
76.  Kominsky, S.L.; Tyler, B.; Sosnowski, J.; Brady K.; Doucet, M.; Nell, D.; Smedley, J.G., III; 
McClane, B.;  Brem, H.; Sukumar, S. Clostridium perfringens enterotoxin as a novel-targeted 
therapeutic for brain metastasis. Cancer Res. 2007, 67, 7977–7982. 
77.  Santin, A.D.; Bellone, S.; Marizzoni, M.; Palmieri, M.; Siegel, E.R.; McKenney, J.K.; Hennings, 
L.; Comper, F.; Bandiera, E.; Pecorelli, S. Overexpression of claudin-3 and claudin-4 receptors in 
uterine serous papillary carcinoma - Novel targets for a type-specific therapy using Clostridium 
perfringens enterotoxin (CPE). Cancer 2007, 109, 1312–1322. 
78.  Morin, P.J. Claudin proteins in ovarian cancer. Dis. Markers 2007, 23, 453–457. Toxins 2010, 2                               
 
 
1356 
79.  Morin, P.J. Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. 
Cancer Res. 2005, 65, 9603–9606. 
80.  Potala, S.; Sahoo, S.K.; Verma, R.S. Targeted therapy of cancer using diphtheria toxin-derived 
immunotoxins. Drug Discov. Today 2008, 13, 807–815. 
81.  Kreitman,  R.J.;  Pastan,  I.  Immunotoxins in the treatment of refractory hairy cell leukemia. 
Hematol. Oncol. Clin. N. Am. 2006, 20, 1137–1151. 
82.  Kakutani, H.; Kondoh, M.; Saeki, R.; Fujii, M.; Watanabe, Y.; Mizuguchi, H.; Yagi, K. Claudin-
4-targeting of diphtheria toxin fragment A using a C-terminal fragment of Clostridium perfringens 
enterotoxin. Eur. J. Pharm. Biopharm. 2010, 75, 213–217. 
83.  Yuan, X.Q.; Lin, X.J.; Manorek, G.; Kanatani, I.; Cheung, L.H.; Rosenblum, M.G.; Howell, S.B. 
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing 
the claudin-3 and claudin-4 receptors. Mol. Cancer Ther. 2009, 8, 1906–1915. 
84.  Michl, P.; Buchholz, M.; Rolke, M.; Kunsch, S.; Lohr, M.; McClane, B.; Tsukita, S.; Leder, G.; 
Adler, G.; Gress, T.M. Claudin-4: A new target for pancreatic cancer treatment using Clostridium 
perfringens enterotoxin. Gastroenterology 2001, 121, 678–684. 
85.  Santin, A.D.; Cane, S.; Bellone, S.; Palmieri, M.; Siegel, E.R.; Thomas, M.; Roman, J.J.; Burnett, 
A.;  Cannon,  M.J.;  Pecorelli,  S.  Treatment of chemotherapy-resistant human ovarian  cancer 
xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens 
enterotoxin. Cancer Res. 2005, 65, 4334–4342. 
86.  Meertens, L.; Bertaux, C.; Cukierman, L.; Cormier, E.; Lavillette, D.; Cosset, F.L.; Dragic, T. The 
tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J. Virol. 2008, 
82, 3555–3560. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed under the terms and conditions of  the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 